Sagaliam Acquisition Corp. Acquires Biogenysis and Virogentics
Enzolytics, Inc. announced on September 18 that it sold two of its wholly owned subsidiaries, Biogenysis, Inc. and Virogentics, Inc., to Sagaliam Acquisition Corp. in a transaction valued at $450 million. Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. Biogenysis uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus... Read More »
Redefine Healthcare Expands Presence in New Jersey
On September 18 Redefine Healthcare announced it was merging with Mercer-Bucks Orthopedics. Mercer-Bucks Orthopedics is an orthopedic practice. It operates four locations in New Jersey and one in Pennsylvania. According to its website, the practice is run by 13 physicians, five physician assistants, eight physical therapists and two occupational therapists. Redefine Healthcare is a leading multidisciplinary medical practice dedicated pain management and orthopedics. It has 19 locations in New Jersey. With an expanded team of more than 70 providers, patients of the merged company can now receive comprehensive treatment for sports medicine injuries, joint... Read More »
Pharmanovia Acquires CNS Portfolio From Sanofi
Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023. Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a... Read More »
The Crossover of Rehabilitation and Behavioral Health
Traditionally, Behavioral Health Care (BHC) and Rehabilitation have been seen as two separate healthcare sectors with little overlap, but, in the wake of both COVID-19 and the third wave of the opioid crisis, that may (and should) change as more companies discover the potential benefits of pairing both types of healthcare providers together. To get a thorough understanding of each market, we need to define the sectors and what type of care is provided. Rehabilitation provides services related to physical therapy for sports injuries, brain damage accidents, post-acute care physical rehabilitation and work-place injuries. BHC consists of providers that focus on treating mental health. This... Read More »
Best Buy Partners with Geisinger for Chronic Care Management
Minneapolis-based retail giant Best Buy has announced plans to expand its at-home care offerings through a partnership with Pennsylvania-based healthcare system Geisinger Health. Best Buy and Geisinger plan to co-create a chronic care management package in which Best Buy will supply patient engagement and monitoring, and Geisinger will bring clinical expertise to healthcare organizations. Geisinger Health comprises 10 hospitals, as well as a health plan with more than half a million members. The health system has 25,000 employees and more than 1,700 physicians. The health system also has 133 primary care and specialty clinic sites and serves 67 counties. In 2021, Geisinger... Read More »
Agilent Technologies Divests Resolution Bioscience
Agilent Technologies, Inc. announced it is selling Resolution Bioscience Inc. to Exact Sciences Corp. Financial terms of the agreement were not disclosed and are not material to either party. According to data captured in the LevinPro HC database, this transaction represents the 108th Biotechnology acquisition of 2023. Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis. Exact Sciences is a molecular diagnostics company which focuses on the early... Read More »
Waud Capital Partners Launches PharmAlliance Holdings
Waud Capital Partners, a growth-oriented middle market private equity firm based in Chicago, announced on September 14 that it launched PharmAlliance Holdings, LLC. This was done in partnership with Mark Bouck, who will serve as Chief Executive Officer of the platform. PharmAlliance Holdings is a diversified pharmaceutical and life sciences services provider focused on discovery, development and commercialization solutions. Its services span across the drug life cycle for pharmaceutical, biotechnology, life sciences and medical device companies. In conjunction with its launch, PharmAlliance invested in BioBridges, a drug development consulting business serving... Read More »
CLS Health Acquires Southeast Houston Cardiology
CLS Health, formerly known as Clear Lake Specialties, has finalized the acquisition of Southeast Houston Cardiology. The acquisition extends CLS Health’s geographical reach in the Houston MSA. According to data captured in the LevinPro HC database, this transaction represents the 388th Physician Medical Groups acquisition of 2023, 24 of them in the cardiology specialty. Financial terms of the deal were not disclosed. Southeast Houston Cardiology is a Texas-based cardiology practice that’s been serving Pasadena, Clear Lake, Webster and the surrounding area for more than twenty years. According to its website, the practice has six providers on staff. CLS Health is a... Read More »